Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
13
CMND Quote, Financials, Valuation and Earnings
Last price:
$2.71
Seasonality move
:
-26.17%
Day range:
$2.58 - $2.88
52-week range:
$2.36 - $87.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.86x
Volume:
79.5K
Avg. volume:
752.5K
1-year change:
-94.24%
Market cap:
$4.1M
Revenue:
--
EPS (TTM):
-$0.85
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Clearmind Medicine, Inc. has -- downside to fair value with a price target of -- per share.
CMND vs. S&P 500
-
Over the past 5 trading days, Clearmind Medicine, Inc. has underperformed the S&P 500 by -7.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Clearmind Medicine, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Clearmind Medicine, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Clearmind Medicine, Inc. reported revenues of --.
Earnings Growth
-
Clearmind Medicine, Inc. has grown year-over-year earnings for 12 quarters straight. In the most recent quarter Clearmind Medicine, Inc. reported earnings per share of -$0.25.
Enterprise value:
641.5K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$48K
Return On Assets:
-65.04%
Net Income Margin (TTM):
--
Return On Equity:
-158.33%
Return On Invested Capital:
-155.61%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-07-31 | 2024-07-31 | 2025-07-31 | 2024-07-31 | 2025-07-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$77.5K | -$43.6K | -$48K | -$15.2K | -$12.5K | |
| Operating Income | -$5.8M | -$5.9M | -$5.8M | -$1.5M | -$1.4M | |
| EBITDA | -$5.7M | -$5.8M | -$5.7M | -$1.5M | -$1.4M | |
| Diluted EPS | -$80.07 | -$13.21 | -$0.85 | -$0.59 | -$0.25 | |
| Period Ending | 2021-07-31 | 2022-07-31 | 2023-07-31 | 2024-07-31 | 2025-07-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.3M | $691.9K | $4.4M | $8M | $3.8M | |
| Total Assets | $5.7M | $894.8K | $4.5M | $8.2M | $4M | |
| Current Liabilities | $352.3K | $611.2K | $1.7M | $4.7M | $2.9M | |
| Total Liabilities | $352.3K | $611.2K | $1.7M | $4.7M | $2.9M | |
| Total Equity | $5.3M | $283.6K | $2.8M | $3.5M | $1.1M | |
| Total Debt | -- | $38K | -- | $60.9K | $28.4K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-07-31 | 2024-07-31 | 2025-07-31 | 2024-07-31 | 2025-07-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.7M | -$4.4M | -$4.6M | -$1.1M | -$1.2M | |
| Cash From Investing | $51.3K | $77.8K | -$366.9K | $33.3K | $112.6K | |
| Cash From Financing | $9.3M | $8.1M | $732K | $443.2K | -$3.1K | |
| Free Cash Flow | -$5.7M | -$4.4M | -$4.6M | -$1.1M | -$1.2M | |
CMND
Sector
Market Cap
$4.1M
$27.9M
Price % of 52-Week High
3.14%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-14.5%
-1.49%
1-Year Price Total Return
-94.24%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.99
200-day SMA
Sell
Level
$35.03
Bollinger Bands (100)
Sell
Level
15.06 - 45.28
Chaikin Money Flow
Sell
Level
-11.4M
20-day SMA
Sell
Level
$4.68
Relative Strength Index (RSI14)
Sell
Level
17.29
ADX Line
Sell
Level
28.64
Williams %R
Buy
Level
-87.7102
50-day SMA
Sell
Level
$19.67
MACD (12, 26)
Sell
Level
-4.46
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
3.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.9018)
Sell
CA Score
(Annual)
Level (-5.2609)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.9121)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
Stock Forecast FAQ
In the current month, CMND has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CMND average analyst price target in the past 3 months is --.
-
Where Will Clearmind Medicine, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Clearmind Medicine, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Clearmind Medicine, Inc.?
Analysts are divided on their view about Clearmind Medicine, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Clearmind Medicine, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Clearmind Medicine, Inc.'s Price Target?
The price target for Clearmind Medicine, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CMND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Clearmind Medicine, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CMND?
You can purchase shares of Clearmind Medicine, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Clearmind Medicine, Inc. shares.
-
What Is The Clearmind Medicine, Inc. Share Price Today?
Clearmind Medicine, Inc. was last trading at $2.71 per share. This represents the most recent stock quote for Clearmind Medicine, Inc.. Yesterday, Clearmind Medicine, Inc. closed at $2.74 per share.
-
How To Buy Clearmind Medicine, Inc. Stock Online?
In order to purchase Clearmind Medicine, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CMND Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CMND
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
3.86x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
CMND
Sector
Revenue growth
--
4.62%
Earnings growth
58.2%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
CMND
Sector
Profitability FY 2024
-$51.1K
$3.6M
Return on invested capital
-155.61%
-31.87%
Return on assets
-65.04%
-28.18%
Return on equity
-158.33%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
CMND
Sector
Total cash
$3.5M
$26.4M
Short term investments
$289.4K
$25.7M
Total assets
$7.3M
$76.9M
Long term debt
$28.4K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
